Covid-19 confirmed cases in Finland and other countries

(move mouse or touch to see the trend in different countries) 

Source: Our world in data

Domestic
Tools
Typography

Mobidiag Ltd. announced yesterday that it has received emergency use authorisation in Finland for its Amplidiag® COVID-19 molecular diagnostic test for the rapid detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Amplidiag® COVID-19 is now available for use in Finland*. The test will be run for routine use at the main clinical laboratories in Finland (Helsinki University Hospital (Huslab), SYNLAB and Mehiläinen) doubling Finnish testing capacity and allowing testing coverage for most of the country. 

The process for obtaining emergency use authorization is now ongoing in Sweden, UK and France. Mobidiag will register this test for CE-IVD mark and it should be available for widespread use in Europe in the coming weeks through Mobidiag’s sales teams and local distributors.

The Amplidiag® COVID-19 assay allows qualitative determination of SARS-CoV-2 (orf1ab and N genes) from nasopharyngeal swabs. The test runs on Mobidiag’s Amplidiag® Easy platform, which enables to clinicians an optimized sample screening process with automated DNA extraction and PCR plate setup. Based on well-established high-throughput PCR technology, it can process 48 samples in less than three hours.

In addition, Mobidiag is developing Novodiag® COVID-19, a molecular diagnostic test using its Novodiag® system for the rapid and on-demand detection of SARS-CoV-2. This test will complement Amplidiag® COVID-19 in enabling clinicians around the world to detect COVID-19 infections early, support decisions in managing efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care.

Tuomas Tenkanen, CEO of Mobidiag, said, “At Mobidiag, we recognise that we have a responsibility to support healthcare systems during this extraordinary situation and we are focusing our efforts in this endeavour. There is an urgent and growing need for reliable diagnostic solutions for the early detection of COVID-19, and Mobidiag has been able to leverage its capabilities and existing technologies to develop new diagnostic solutions quickly.

Established in 2000, Mobidiag has served the European clinical diagnostics market with its multiplex Prove-it™ product family since 2008.

In 2013, Mobidiag (Finland) merged with a diagnostic platform developer Genewave (France) and a stool-based clinical assay development company Amplidiag (Finland). As a result, complementing capabilities and offering were gathered to offer industry-leading diagnostic solutions.

HT

Partners